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Abstract  
PURPOSE:  The question of whether mesenchymal stromal cells (MSCs) home to injured 
kidneys remains a contested issue. To try and understand the basis for contradictory findings 
reported in the literature, our purpose here was to investigate whether MSC homing capacity 
is influenced by administration route, the type of injury model used, and/or the presence of 
exogenous macrophages. 
PROCEDURES: To assess the viability, whole body biodistribution and intra-renal 
biodistribution of MSCs, we used a multi-modal imaging strategy comprising bioluminescence 
and magnetic resonance imaging (MRI). The effect of administration route (venous or arterial) 
on the ability of MSCs to home to injured renal tissue, and persist there, was assessed in a 
glomerular injury model (induced by the nephrotoxicant, adriamycin), and a tubular injury 
model induced by ischaemia-reperfusion injury (IRI). Exogenous macrophages were used as a 
positive control because these cells are known to home to injured mouse kidneys. To assess 
whether the homing capacity of MSCs can be influenced by the presence of exogenous 
macrophages, we used a dual-bioluminescence strategy that allowed the whole body 
biodistribution of the two cell types to be monitored simultaneously in individual animals.  
RESULTS:  Following intravenous administration, no MSCs were detected in the kidneys, 
irrespective of whether the mice had been subjected to renal injury. After arterial administration 
via the left cardiac ventricle, MSCs transiently populated the kidneys, but no preferential 
homing or persistence was observed in injured renal tissue after unilateral IRI. An exception 
was when MSCs were co-administered with exogenous macrophages; here, we observed some 
homing of MSCs to the injured kidney. 
CONCLUSIONS: Our findings strongly suggest that MSCs do not home to injured kidneys.  
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Introduction 
Numerous studies have shown that mesenchymal stromal cells (MSCs) from various sources, 
including bone marrow, adipose tissue and the umbilical cord, can improve renal function and 
ameliorate tissue damage following administration into rodents with kidney injury [1]. 
However, the mechanisms are ill-defined and it is not clear if the MSCs engraft in injured 
kidneys or not. Some studies have presented data that suggest MSCs home to injured kidneys, 
and that renal engraftment is necessary for their therapeutic effects [2-3], whereas others 
suggest that MSCs do not engraft and that any therapeutic benefit is likely due to paracrine or 
endocrine factors [4-5]. If the former scenario were correct, it would be expected that MSCs 
administered intravenously (IV) might be less effective in rodent kidney injury models than 
MSCs administered intra-arterially (i.e., via the renal artery, carotid artery, descending aorta or 
left cardiac ventricle). This is because following IV administration, most cells become trapped 
in the lungs due to the pulmonary first-pass effect [6-8], whereas intra-arterial administration 
delivers more cells to the kidneys [9]. In support of this, a meta-analysis has indicated that the 
intra-arterial route gives greater benefit in rodents than the IV route [10]. However, 
biodistribution studies present contradictory findings, with some showing that even after 
injecting MSCs into the renal artery, they are mainly localised to the lung [11], whereas others 
show that in animals with renal injury, cells administered arterially are mostly localised in the 
kidney [12]. These discrepancies could result from a variety of reasons; for instance, different 
methods being used to induce renal impairment; MSCs being administered at different time-
points following injury; different tracking methods being used to determine the location of the 
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MSCs. Cell tracking methods that rely solely on identifying MSCs on histological sections 
using fluorescence microscopy can be particularly problematic due to the fact that the kidney 
emits intense autofluorescence, which can be increased even further following renal injury 
[13].  
To obtain more accurate information about MSC biodistribution in vivo and ascertain how this 
might be affected by the route of administration, we have previously applied a bi-modal 
imaging approach comprising bioluminescence imaging (BLI) and magnetic resonance 
imaging (MRI) to respectively monitor the whole body and intra-renal biodistribution of mouse 
MSCs in mice [9]. This was achieved by introducing the firefly luciferase (FLuc) reporter into 
the MSCs to permit BLI following administration of the substrate, luciferin, and by labelling 
the MSCs with superparamagnetic iron oxide nanoparticles (SPIONs) so that they could be 
identified using MRI. In addition to facilitating whole-body imaging, an advantage of FLuc-
BLI is that it is an indicator of living cells. A key advantage of MRI is that the spatial resolution 
is much higher than with BLI, so that it is possible to determine the position of SPION-labelled 
cells within the kidney [14]. By applying this bi-modal strategy to healthy mice, we found that 
MSCs administered IV remained trapped in the lungs, but those injected into the left cardiac 
ventricle could populate the kidneys. Irrespective of administration route, however, most 
primary MSC types, including human bone marrow-derived MSCs, did not persist in any organ 
beyond 48 h. 
In the current study, using two different mouse injury models where the site of injury is 
primarily the glomeruli (adriamycin model) or the proximal tubules (ischaemia reperfusion 
injury (IRI) model), we have applied this bi-modal imaging strategy to determine if mouse 
MSCs home to injured kidneys following systemic administration, and whether they persist 
there. As a positive control cell population, we have used the RAW 264.7 mouse macrophage 
line which had been reported to ameliorate renal injury in mice [5] and can home to injured 
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tissues [15]. Finally, given that some studies suggest that the therapeutic effects of MSCs are 
mediated by macrophages [5, 16], we have used a dual-bioluminescence imaging strategy 
recently developed in our lab that comprises FLuc and a NanoLuc (NLuc)-based 
bioluminescence resonance energy transfer (BRET) reporter [17], to investigate whether the 
biodistribution of FLuc+ macrophages is affected by co-administration of NLuc+ MSCs, and 
vice-versa. 
 
Methods 
Cell Labelling 
The mouse mesenchymal stem/stromal cell (MSC) D1 line was obtained from the American 
Type Culture Collection (CRL-12424) and RAW 264.7 mouse macrophages were obtained 
from the European Collection of Authenticated Cell Cultures (#91062702). Both cell types 
were originally derived from BALB/c mice [18-19]. Cells were transduced with a lentiviral 
vectors encoding a bicistronic construct of Firefly Luciferase (FLuc) and ZsGreen under 
control of the constitutive promoter EF1α or a previously described bioluminescence resonance 
energy transfer (BRET) reporter [17], also under the control of EF1α. The production and 
titration of viral particles was performed using established protocols [20]. The cells were 
transduced with a multiplicity of infection of 5 in the presence of polybrene (8 µg/mL) for the 
MSCs and without polybrene for the RAW macrophages. At least 90% of the MSCs expressed 
the transgenes after transduction whereas macrophages, due to the poor transduction efficiency, 
were sorted based on ZsGreen fluorescence using an Aria fluorescence-activated cell sorter 
(BD Biosciences). Both cell lines were maintained in Dulbecco's Modified Eagle's medium 
with 10% foetal calf serum at 37 °C in a humidified incubator with 5% CO2. 
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Iron oxide labelling for MR detection was carried out by co-incubation of the cells with the 
particles for a period of 24 h prior to administration to mice, after which cells were washed and 
harvested for injection. Cationic SPIONs produced in-house [21-22] were used for labelling 
the MSCs (labelling concentration: 25 µg[Fe]/mL; iron content after  labelling: ~ 5 pg[Fe]/cell) 
whereas macrophages were labelled with ferumoxytol (AMAG pharmaceuticals, labelling 
concentration: 20 µg[Fe]/mL, iron content after labelling: ~ 6.5 pg[Fe]/cell). The use of 
different SPIONs is required because each cell type responds differently to such materials e.g: 
ferumoxytol alone does not effectively label MSCs [23], but do label RAW macrophages 
without affecting their morphology or viability [24]. In all experiments, cells were trypsinised, 
pelleted, resuspended in ice-cold phosphate buffered saline (PBS) and kept on ice until 
injection. The cell suspension (100 µL) was administered to mice intravenously (IV) via the 
tail vein or intracardially (IC) via the left ventricle of the heart via ultrasound guidance 
(Prospect system, S-Sharp, Taiwan) [9]. 
 
Models of kidney injury 
BALB/c mice (Charles River, UK) were housed in individually ventilated cages under a 12 h 
light/dark cycle, with ad libitum access to standard food and water. All animal experiments 
were performed under a licence granted under the UK Animals (Scientific Procedures) Act 
1986 and were approved by the University of Liverpool ethics committee. ARRIVE guidelines 
were followed to report animal experiments. This mouse strain is expected to accept the two 
cell lines used in this study, irrespective of animal’s immune status. 
Adriamycin nephropathy was induced in female BALB/c SCID mice by injecting adriamycin 
(ADR, doxorubicin hydrochloride, Tocris, UK) IV at 6.3 mg/kg body weight (BW) in 0.9% 
saline. Cells were administered 14 days post ADR, when renal impairment is observed [25]. 
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For IRI, male mice were anaesthetised with isoflurane and a flank incision was made for 
unilateral clamping of the renal pedicle for 40 min, using an atraumatic vascular clamp. 
Subsequently, the vascular clamp was removed and restoration of renal blood flow confirmed 
visually prior to repair of muscle and skin layers. In this model, renal impairment is observed 
24 h post-clamping [26] and cells were administered at this time point.    
 
Imaging 
For bioluminescence imaging, a subcutaneous injection of luciferin (150 mg/kg body weight, 
Promega, UK) was administered to mice under anaesthesia, which were imaged 15 min later 
in a bioluminescence imager (IVIS Spectrum, Perkin Elmer, UK). Imaging data were 
normalised to the acquisition conditions and expressed as radiance 
(photons/second/cm2/steradian (p/s/cm2/sr)). For ex vivo BLI, mice were culled 10 min post 
administration of luciferin, after which organs were harvested and immediately imaged. 
Bioluminescence signals of whole animals or individual organs ex vivo were quantified by 
drawing regions of interest (ROIs) from which the total flux (photons/second) was obtained. 
For simultaneous tracking of MSCs and RAWs in the same animal, MSCs were transduced 
with a BRET reporter and imaged in vivo and ex vivo as previously reported [17]. In brief, the 
imaging protocol involves the tail vein cannulation of the mice, injection of the substrates 
(furimazine or luciferin) IV and sequential acquisition of data. The BRET signal from the 
MSCs is obtained immediately after furimazine injection and because the half-life of this 
substrate is very short, the signal is cleared within approximately 10 minutes. This allows 
subsequent injection of luciferin and collection of Fluc signal from the RAW macrophages in 
the same imaging session, without crosstalk between the different reporter systems.  Ex vivo 
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imaging involves a similar method, but the firefly luciferase signal is collected before the 
BRET signal [17]. 
MR data was obtained with a Bruker Avance III console interfaced to a 9.4T magnet system 
(Bruker Biospec 94/20 USR) and a 4-channel receive-only abdominal surface coil in 
combination with a 72 mm resonator. Mice were imaged at baseline (before injury) and at 
multiple time points post administration of SPION-labelled cells.  A gated Fast Low-Angle 
Shot (FLASH) T2* sequence was used with the following acquisition parameters:  TE: 5.5 ms, 
TR: 262.5 ms, flip angle: 20o, matrix size: 386x386 pixels, field of view: 35x35 mm, slice 
thickness: 0.5 mm, number of slices: 20, averages: 3, acquisition time: 5 min, 35s. T2* 
relaxation times were obtained from a T2* map by drawing ROIs around the cortex of the kidney 
or a region of the liver as previously described [9]. The T2* maps were obtained with a multi-
gradient echo (MGE) sequence with 8 echoes starting at 4.5 ms with 4.5 ms increments and 
TR: 900 ms, flip angle: 50o, matrix size: 256x256 pixels, field of view: 35x35 mm, slice 
thickness: 0.5 mm, number of slices: 20, averages: 2, acquisition time: 5 min, 45s: For ex vivo 
imaging of kidneys the organs were fixed in formaldehyde, embedded in agarose and imaged 
with a FLASH T2* sequence with  following acquisition parameters: TE: 6.3 ms, TR: 1300 ms, 
flip angle: 20o, matrix size: 400x400 pixels, field of view: 17x17 mm, slice thickness: 0.2 mm, 
number of slices: 70, averages: 24, acquisition time: 3 h, 20 min. 
 
Results 
A combination of MRI and BLI allows the in vivo imaging of MSC delivery to the kidneys, 
but does not provide evidence of preferential persistence or homing to the injured kidney. 
We applied an imaging protocol involving the double labelling of MSCs with SPIONs and 
FLuc to allow their imaging via MRI and BLI, respectively. In MRI, the SPION label creates 
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local magnetic field inhomogeneities in the areas where cells are delivered to, leading to decay 
of transverse magnetisation, which is observed as hypointense (dark) contrast in T2*-weighted 
imaging. This is usually used to image a specific organ or body region. BLI, on the other hand 
allows assessment of the whole-body distribution of cells. SPION+FLuc+ MSCs were 
administered into the left cardiac ventricle of mice with adriamycin-induced injury or IRI. 
Irrespective of the injury model, MR imaging performed within a few hours of cell 
administration showed hypointense contrast in the renal cortices (Fig. 1a). This confirmed that 
administration via the arterial route leads to successful delivery of the cells to the kidneys. 
Hypointense contrast was additionally observed in the medulla of kidneys following IRI (Fig. 
1a, blue arrows); however, this phenomenon was also observed in the absence of administered 
cells (ESM Fig. 1), suggesting a surgery-specific effect. The contrast in the renal cortices was 
progressively lost in the subsequent days, indicating that the cells were cleared from the 
kidneys. Quantification of the T2* relaxation time, the time constant that describes the decay of 
transverse magnetisation, revealed a statistically significant reduction on the administration 
day but recovery to baseline values in the following days (Fig. 1b, c). For mice that underwent 
IRI, we compared the relaxation times of injured kidney with that of the uninjured contralateral 
kidney but saw no differences between the two (ESM Fig. 2a). In the liver of IRI mice, the T2* 
relaxation time dropped progressively throughout the experimental period to values that were 
significantly different from baseline by days 1 and 2, whereas the T2* relaxation time was 
significantly lower than baseline on all days after cell administration in the ADR model (Fig. 
1b, c). This suggests that SPIONs are transported from the kidneys to the liver in the days 
subsequent to cell administration. BLI revealed whole body distribution of MSCs on the 
administration day, as anticipated from injection via the arterial route. A progressive loss of 
signal intensity was seen in the days following cell administration, suggesting cell death. By 
day 2, only a weak signal was detected in the kidneys, which is consistent with the loss of MR 
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contrast. Taken together, these data suggest loss of MSCs from the kidneys via progressive cell 
death, following which, the SPION label is transported to the liver, most likely by the host’s 
reticuloendothelial system. 
 
Similarly to MSCs, RAW macrophages are short-lived in the kidneys but populate the 
liver. 
Having observed no persistence of MSCs in the kidneys, we investigated whether macrophages 
have a different fate. From here, our study focuses on the unilateral IRI model given the 
presence of an internal control kidney in each animal. A total of 5x106 cells were administered, 
based on a dose-finding study that showed that these cells are well tolerated when injected via 
the left ventricle of the heart [9]. MR imaging revealed a similar renal distribution as observed 
with the MSCs, with strong negative contrast in the cortex on the administration day and 
progressive loss on the following days (Fig. 2a). Indeed, the changes in T2* relaxation times in 
the renal cortices and liver follow the same behaviour as we observed for the MSCs (Fig. 2b), 
and as before, no differences were seen when comparing the injured kidney with the control 
kidney (ESM Fig. 2b). However, when animals were analysed individually, we noticed that 
some appeared to display a greater negative contrast in the injured kidney on the administration 
day (ESM Fig. 3). BLI imaging displayed a different distribution to that seen with the MSCs, 
with a moderate loss of signal on day 1, but an increase in signal in the spine and liver by day 
2 suggesting that the cells had populated these organs (Fig. 2c). This implies that for this cell 
type, the reduction in T2* relaxation time in the liver was probably a combination of two 
components: (i) SPION debris from RAW macrophages that have died after administration and 
(ii) viable SPION+ FLuc+ RAW macrophages that home to the liver. The differences in cell 
fate between the two cell types are also evident when mice are imaged ventrally (ESM Fig. 4), 
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with a marked signal originating from the liver of mice that receive macrophages but not from 
those that receive MSCs.  
To confirm the MR data obtained in vivo, we scanned the kidneys post-mortem at a higher 
resolution. Ex vivo imaging of the kidneys of mice that received MSCs exhibited the same 
features as observed in vivo: (i) hypointense contrast in the renal cortex on day 0, which was 
lost in subsequent days; (ii) no major differences between the distribution of cells in the cortex 
of healthy and injured kidneys; and (iii) a darkening of the medulla of the injured kidney (Fig. 
3). Imaging of the kidneys of animals that received macrophages displayed a similar pattern, 
but the contrast in the cortex was stronger which is likely a consequence of the higher injection 
dose (5x106 RAWs vs 106 MSCs), meaning that more cells are present in the kidneys on the 
administration day. Interestingly, a careful examination of the images revealed that more 
hypointense spots were present in the injured kidney, particularly on day 1, when compared to 
the healthy kidney (Fig. 3, red arrows). Taken together, the in vivo and ex vivo MR imaging of 
macrophages suggest a greater accumulation or persistence of cells in the injured kidney, but 
this could not be unambiguously demonstrated in a quantitative manner using this imaging 
modality.  
 
BLI ex vivo provides improved sensitivity and reveals distinct behaviour between 
macrophages and MSCs 
To quantitatively determine whether macrophages do preferentially persist in the injured 
kidney as suggested by the MR data, mice were culled 24 h post cell administration for ex vivo 
imaging of the organs via bioluminescence. Imaging of the lungs, liver, spleen, heart and 
kidneys revealed that cells were present in all major organs at this time point with lungs and 
liver displaying the strongest signal intensity (Fig. 4). Analysis of the signal intensity in each 
of the kidneys showed an increase in the mean signal in the injured kidneys when mice received 
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the MSCs IC, but this was not statistically significant (p=0.16, Fig. 4a). Mice that received the 
macrophages IC, on the other hand, displayed a statistically significant difference between 
kidneys, with the injured having a greater bioluminescence intensity (p=0.032, Fig. 4b).  
Because it is known that RAW macrophages are able to bypass the lung vasculature when 
administered IV [9], we assessed whether this route of administration can also lead to cells 
accumulating preferentially in the injured kidney. Administration of 107 cells via this route 
confirmed their ability to extravasate the lungs, with cells also populating the liver, spleen and 
kidneys (Fig. 4c). A stronger bioluminescence intensity was detected in the injured kidneys 
(p=<0.001) suggesting a homing effect where these cells actively migrate to the site of 
ischaemic injury. Of note, our experimental setup only allowed us to detect those differences 
when imaging the organs ex vivo. Our attempts to quantify the signal emanating from the 
kidneys in vivo were unsuccessful due to the presence of cells in other organs, the surgical scar 
overlying the injured kidney and the low spatial resolution of BLI (ESM Fig. 5).  
 
Multiplex imaging allows the tracking of each cell independently and suggests no 
crosstalk between RAW macrophages and MSCs.  
Having determined differences in the homing and persistence of MSCs and RAW macrophages 
in mice with IRI, we next sought to identify whether the biodistribution of the MSCs could be 
influenced by the presence of exogenous macrophages. For this, we co-injected MSCs and 
RAW macrophages into the same mice and applied a method to track them individually, using 
a combination of NanoLuc-based BRET reporter and FLuc. Shortly following IC 
administration, both cell types showed a similar whole body distribution, with good co-
localisation of the MSC and macrophage signal on day 0 (Fig. 5a). On day 1, the signal 
weakened, in agreement with the data in Fig. 1 and 2, with some MSCs still present in the 
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abdominal area, including the kidneys, and brain, whereas the macrophage signal was most 
intense in the spine. A different scenario emerged when the cells were administered IV, with 
both types of cells being found exclusively in the lungs on the day of administration.  A strong 
reduction in signal intensity was observed by day 1, with MSCs still located in the lungs, 
whereas macrophages were found not only in the lungs, but also in the abdomen. 
Ex vivo imaging of organs on day 1 showed similar results to those obtained when the cells 
were administered individually. After IC administration, MSCs were found in most organs 
including the kidneys, with a stronger signal intensity in the injured kidney (Fig. 5b). In contrast 
to the data shown in Fig. 4a, we saw a statistically significant difference between the kidneys 
in this experimental setup. We have previously shown that MSCs expressing this BRET 
reporter have a light output much greater than that of cells expressing FLuc [17] and it is thus 
possible that these results reflect a greater sensitivity of the reporter, allowing us to detect a 
statistically significant difference which was not observed with FLuc. However, it is also 
possible that the increased numbers of RAW macrophages in the injured kidney may restrict 
blood flow through the glomerular capillaries, causing a transient accumulation of MSCs.  
Following IV administration, no MSCs were detected in any organ apart from the lungs (Fig 
5b). RAW macrophages, on the other hand, produced a stronger signal in the injured kidney 
that was statistically significant irrespective of the administration route, demonstrating that 
their homing is not affected by co-administration of MSCs.   
 
Discussion 
MSCs are efficacious in various preclinical models of renal injury [10], but whether their 
therapeutic effects are dependent on their ability to populate the kidneys is a contested issue; 
for instance, some reports have suggested that efficacy is improved with enhanced renal 
homing of MSCs [2], while others suggest that improvements in renal health occur in the 
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absence of homing [4-5]. To determine whether MSCs home to injured kidneys or not, we used 
multimodal imaging to assess MSC biodistribution following IV and IC administration in two 
different mouse models of renal injury. In contrast to macrophages, which served as a positive 
control, we found little evidence of any MSC renal homing capacity. 
We have previously shown that stem cell administration via the intracardiac route prevents the 
well-known pulmonary first-pass effect, allowing cells to reach the kidneys [9]. However, in 
this previous study only healthy mice were used. Here, we sought to assess whether the 
presence of a glomerular (adriamycin) or tubular (IRI) injury affects the persistence and 
survival of the cells in this organ. In the former model, both kidneys are injured, requiring 
comparison with a control group. Comparison with our previous data, which involved the same 
mouse strain, same MSC line and the same labelling/imaging strategy [9] reveals that survival 
and persistence are not affected by renal injury, with the great majority of the cells dying or 
being cleared from the kidneys in the days subsequent to their administration. When compared 
to the ADR model, the unilateral ischemia/reperfusion model provides the advantage of an 
internal control within the same animal. The behaviour of the cells in the IRI model was similar 
to that observed with healthy or adriamycin-injured animals; that is, an initial accumulation 
was observed in the renal cortices followed by cell death and/or rapid clearance. A similar 
dynamic was observed when injecting macrophages. It is important to note that the ADR is a 
model of glomerular injury, while IRI predominantly damages the proximal tubules. 
Nevertheless, MRI signal after IC administration was seen predominantly in the cortices, but 
not in the renal tubules, irrespective of the injury model. We have previously shown that when 
administered IC, cells that reach the kidney are found predominantly in the glomeruli [25], 
which are highly vascularised. These observations indicate that although the IC route results in 
good delivery of MSCs to the kidneys, their distribution in this organ likely relates to vascular 
entrapment rather than to active homing to the site of injury. 
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Bioluminescence imaging the organs ex vivo offer greater sensitivity because there is much 
less signal attenuation in the absence of surrounding tissue. On the first day following 
macrophage administration, a difference in the signal intensity between the injured and control 
kidney in the IRI model was observed, which has two important implications.  
The first concerns the sensitivity of the technologies used here. The combination of MRI and 
BLI in vivo provided important information to whether cells reached the kidneys as well as 
their intra-renal distribution and long-term survival, but was not sufficiently robust to allow us 
to detect subtle differences in signal between the two kidneys. Although in the case of 
macrophages, qualitative differences were seen between the kidneys of individual animals via 
MRI in vivo, these were not reflected when the mean relaxation time of whole groups was 
compared. This shows the need to confirm in vivo data post mortem.  
The second implication concerns the biological response of administered cells to the renal 
injury. Administration of MSC and RAWs via the IC route led to a stronger BLI signal in the 
injured kidneys on day 1, implying the presence of a greater number of cells. We have not yet 
established the specific mechanisms on which the stronger signals in the injured kidneys are 
based, but important questions arise: Are the administered cells attracted to the site of injury 
due to local chemokine release? Is the phenomenon based on physical entrapment due to 
underlying changes in the structure of the kidney as a result of the ischaemic injury? The 
observation that IV injected macrophages also produce a stronger signal in the injured kidney 
suggests that at least for this cell type, chemoattraction likely takes place. Indeed, it is well 
recognized that chemokine-mediated infiltration of macrophages takes place in ischaemic acute 
kidney injury [27].  This has additional implications when their action as a cell therapy is taken 
into consideration, as it suggests that both the venous and arterial routes are effective in 
delivering macrophages to the site of injury. Importantly, the same has not been seen with 
MSCs. Although previous studies have suggested that MSCs bypass the lungs and reach the 
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kidneys after IV administration, most of those studies used imaging methods that are prone to 
false positives e.g. (i) the use of lipophilic dyes [28] that can be transferred to host cells [29], 
or (ii) reliance on histological sections, which can give false positive results due to the increased 
levels of autofluorescence in injured kidneys [13, 29].  
Our imaging with reporter genes that are specific to viable cells provides clear, unambiguous 
evidence that IV administered MSCs do not bypass the lungs in two mouse models of renal 
injury, and is in agreement with our previous data using healthy animals [25]. Thus, any 
positive effects on tissue regeneration and/or repair seen after IV administration of MSCs are 
likely related to mechanisms that do not involve the cells migrating and integrating with the 
renal tissue.  Further, this study reinforces the utility of combining multiple reporter gene 
systems to individually track the dynamics of cell distribution and persistence in different 
organs not only in vivo but also post-mortem in excised tissues.  
 
Conclusions 
By applying an imaging strategy combining BLI and MRI, we have been able to determine that 
the delivery of cell therapies to the kidneys is dependent on cell type and route of administration 
in murine models of renal injury. MSCs do not home to the kidneys and are unable to bypass 
the lungs when administered intravenously. Macrophages, on the other hand, have a capacity 
to home and accumulate preferentially in the injured kidneys, whether they are administered 
via the venous or arterial circulation. Multiplex BLI enabled us to track the biodistribution and 
persistence of each of these different cell types individually in the same animal, revealing that 
their fate is independent of one another. 
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Figures and Legends 
 
Figure 1. In vivo MR/BL imaging provides evidence of MSC delivery to the kidneys, but no 
clear differences in the presence of a kidney injury. (a) MRI of the kidneys at baseline (prior 
to injury) and up to 2 days post intracardiac administration of 106 cells to SCID mice with an 
adriamycin or ischaemia/reperfusion renal injury. On the cell administration day (day 0) 
hypointense contrast was seen in the cortices of the kidneys (red arrows), indicating cell 
delivery. The contrast is lost in subsequent days. In the IRI model, hypointense contrast is seen 
in the medulla of the injured kidney (blue arrows). (b) T2* relaxation time of the kidneys’ 
 24 
 
cortices and liver in the ADR model. (c) T2* relaxation time of the kidneys and liver in the IRI 
model. Time points that do not share the same letters are significantly different from one 
another, p < 0.05 (Tukey's post hoc test). p-values for all comparisons are shown in SI Table 
1.  (d) BLI on cell administration day (day 0) shows whole body distribution of cells, including 
the kidneys but the signal is progressively lost in subsequent days, suggesting cell death.  
 
 
Figure 2. In vivo MR/BL imaging provides evidence of macrophage delivery to the kidneys, 
but no clear differences between injured (left) and healthy (right) kidney. (a) MRI of the 
kidneys at baseline and up to 2 days post administration of 5x106 cells to SCID mice with an 
ischemia/reperfusion injury. On the cell administration day (day 0) hypointense contrast in seen 
in the cortices of the kidneys, indicating cell delivery. The contrast is lost in subsequent days. 
(b) T2* relaxation time of the kidney cortices and livers. Time points that do not share the same 
letters are significantly different from one another, p < 0.05 (Tukey's post hoc test). p-values 
for all comparisons are shown in SI Table 2. (c) BLI on cell administration day (day 0) shows 
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whole body distribution of cells, including the kidneys but the signal changes progressively in 
subsequent days and by day 2 the signal is predominately found in the liver (dashed area) and 
spine. 
 
Figure 3. Ex vivo high resolution MRI supports the findings observed in vivo (Fig. 1, 2). On 
day 1, more hypointense areas appear to be present in the injured kidneys of SCID mice that 
underwent IRI and received macrophages (red arrows). 
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Figure 4. Ex vivo BLI is more sensitive and suggests preferential survival or retention of cells 
in the injured kidney of mice that underwent IRI. (a) 106 MSCs administered IC, (b) 5x106 
RAWs administered IC and (c) 107 RAWs administered IV. Left: representative BLI of 
individual organs on day 1 post cell administration. Organs from the same animal were imaged 
at the same time and under the same acquisition conditions. Lu: Lungs, Li: Liver, S: spleen, H: 
heart, K: healthy kidney, Ki: injured kidney. Right: Quantification of the total flux from each 
of the kidneys. MSC IC, n=6; RAW IC, n=3, RAW IV, n=6.   
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Figure 5. Simultaneous in vivo tracking of MSCs and RAW macrophages co-administered to 
SCID mice that underwent IRI. (a) BLI signal as obtained from MSCs (BRET reporter) or 
Macrophages (Fluc) without any colour scaling, and an overlay with pseudo-colours (red: 
MSCs, green: macrophages). The same images, displayed with a “rainbow” scale for each of 
the conditions, are shown in the ESM Fig. 6. (b, c) Representative images of organs imaged ex 
vivo on day 1 post administration. (b, MSCs; c, RAWs). (d) Quantification of the total flux 
from each of the ex vivo kidneys. IC administration n= 6, IV administration n=7.  
